| Popis: |
Antonia Digklia,1 Ana Dolcan,1 Monika A Kucharczyk,2 Robin L Jones,3 Andrea Napolitano3 1Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, 1011, Switzerland; 2Clinical Practice Research Datalink, MHRA, London, E14 4PU, UK; 3Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UKCorrespondence: Antonia Digklia, Email Antonia.digklia@chuv.chAbstract: Ewing sarcoma (ES) is a rare, highly malignant sarcoma. It usually presents in the second decade of life; however, patients can be diagnosed as early as newborns and as late as in their seventies. ES is most frequently found in the long bones of the extremities and the pelvis. In older patients, ES can also arise in the soft tissues. Currently, there is no standard schedule for surveillance of adult patients with ES after their initial treatment for localised disease, not only for the early detection of recurrence but also for long-term side effects. Follow-up is based on group recommendations using extrapolated data obtained primarily from studies with paediatric patients. The main objective of this review is to summarise the data available on treatment-associated complications in long-term survivors. Furthermore, we provide a set of recommendations for optimising the follow-up of adults ES survivors, as well as for managing the sequelae that result from intensive multimodal treatment.Keywords: Ewing, sarcoma, follow-up, toxicities, survivor, review |
